Table 2.
Examples of drug interactions caused by therapeutic proteins.
| Therapeutic protein | Affected drug | Effect | Reference |
|---|---|---|---|
| INTERFERONS | |||
| INF-α | Theophylline | 30–80% reduced clearance | Williams et al. (1987) |
| INF-β | Theophylline | 26% reduced clearance | Okuno et al. (1993) |
| INF-α | Erythromycin | 15% decreased CYP3A4 activity | Craig et al. (1993) |
| INF-α-2b, INF-β | Warfarin | Increased concentration | Adachi et al. (1995) |
| INF-α | Cyclophosphamide | 60% reduced clearance | Hassan et al. (1999) |
| 140% increased t1/2 | |||
| IFN-α-2b | Caffeine | 60% decreased CYP1A2 activity | Islam et al. (2002) |
| IFN-α-2b | Mephenytoin | 40% decreased CYP2C19 activity | Islam et al. (2002) |
| INTERLEUKINS | |||
| IL-2 | Erythromycin | 50% decreased CYP3A4 activity | Elkahwaji et al. (1999) |
| MONOCLONAL ANTIBODIES | |||
| Muromonab-CD3 | Cyclosporine | Increased concentration | Vasquez and Pollak (1997) |
| Basiliximab | Cyclosporine | Increased concentration | Strehlau et al. (2000) |
| Basiliximab | Tacrolimus | 60% increased concentration | Sifontis et al. (2002) |
| Tocilizumab | Omeprazole | 30% decreased AUC | Zhang et al. (2009) |
| Tocilizumab | Simvastatin | 60% decreased AUC | Zhang et al. (2009) |
| Tocilizumab | Simvastatin | 40–60% decreased AUC | Schmitt et al. (2011) |